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Abstract
Background: Allergic rhinitis (AR) represents a global health problem, affecting 5-50% of the population 
worldwide and numerous classes of pharmacological agents are available for its treatment. Two more popular 
of these drugs are Loratadine and Cetirizine. There are few direct comparator studies between these two drugs 
with inconsistent results.
Materials and Methods: A randomized, double-blind study for comparison the therapeutic effects of 
Loratadine and Cetirizine was conducted in an otolaryngologic clinic of a general hospital. Eighty patients with 
perennial allergic rhinitis were divided into two equal groups. One group received Loratadine 10 mg daily for 
two weeks and the other group Cetirizine 10 mg daily also for two weeks. Alterations of the allergic rhinitis 
symptoms including rhinorrhea, sneezing, nasal itching and nasal obstruction were compared between the two 
groups.
Results: Severity of all four studied symptoms was reduced by both drugs. Although Cetirizine had a little 
more efficacy, their difference was not statistically significant (P>0.05). These two medications were most 
effective in reducing the sneezing and least effective on the nasal obstruction.
Conclusion: Loratadine and Cetirizine can reduce symptoms of the perennialallergic rhinitis but their 
difference is not statistically significant.
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Introduction
Allergic rhinitis (AR) represents a global health 
problem, affecting 5-50% of the 
populationworldwide1-6. However, the prevalence of 
AR may be underestimatedbecause many patients 
self-medicate without consulting aphysician and thus 
are not included in official surveys.
Allergic rhinitis is clinically defined as a 
symptomatic disorder of the nose induced by IgE-
mediated inflammation after allergen exposure. 
Symptoms include rhinorrhea, nasal obstruction, nasal 
itching, and sneezing7,8. Traditionally, AR has been 
subdivided into seasonal AR (SAR) or perennial AR 
(PAR); SAR is triggered by numerous outdoor 
allergens, such as pollens and molds, whereas PAR is 
induced most frequently by indoor allergens, such as 
dust mites, molds, and animal dander.In addition to 
allergen avoidance, suggested treatments for AR 
include H1 receptor antagonists (antihistamines), 
corticosteroids, immunotherapy, intranasal saline 
solutions and leukotriene receptor antagonists.
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Numerous classes of pharmacological agents are 
available for treatment of AR. Although not fully an 
ideal treatment, second-generationantihistamines 
exhibit many desirable properties and provide an 
effective means of symptomatic treatment for allergic 
rhinitis. Two more popular of these drugs are 
Loratadine and Cetirizine. Several clinical studies 
have shown the clinical efficacy ofcetirizine9,10 and 
loratadine11,12, however, there have been few direct 
comparatorstudies between these antihistamines and 
statistically significant differences reported in 
therelief of individual symptoms are small and 
inconsistent13.
This study is conducted to compare clinical efficacy 




Eighty patients aged from 15 to 60 years old who 
were presented with allergic rhinitis to an 
otolaryngologic clinic of a general hospital and who 
met our inclusion and exclusion criteria selected. 
Allergic rhinitis diagnosis was based on patient’s 
signs and symptoms. Patients had allergic rhinitis for 
at least two years, at least three of the four following 
symptoms: rhinorrhea, nasal obstruction, nasal 
itching, and sneezing and had to have pale nasal 
mucosa without purulent discharge. Exclusion 
criteria included the presence of acute or chronic 
sinusitis, nasal polyposis, significant nasal septal 
deviation, nasal septal perforation and recent nasal or 
sinus surgery. Also they should not receive any 
antihistamine, Cromolyn, decongestant or 
corticosteroid (topical or systemic) within the 
preceding 2 weeks. Pregnant or lactating ones and 
patients with head and neck cancer, human 
immunodeficiency virus-related nasal disease, cystic 
fibrosis and renal, hepatic pulmonary or 
cardiovascular disease were also excluded.
Study design
A prospective randomized, parallel-group, double-
blind study design was used. All patients were 
required to comply with the study protocol which was
explained to them with both oral and written 
instructions. Patients were randomized into 2 groups 
of 40 each to receive either Loratadine 10 mg or 
Cetirizine10 mg daily for two weeks.
Four symptoms of allergic rhinitis; rhinorrhea, 
sneezing, nasal itching and nasal obstruction were 
assessed and scored before and after treatment in each 
group.
For rhinorrhea, nasal itching and nasal obstruction 
symptoms were scored as follows: 0. none, not 
noticeable, 1. mild, noticeable but not bothersome, 2. 
moderate, noticeable and bothersome some of the 
time, 3. severe, bothersome most of the time and/or 
very bothersome some of the time. Sneezing was 
scored as follows: 0. less than 5 times daily, 1. 6-10 
times daily, 2. 11-15 times daily, 3. more than 15 
times daily.
Statistical analysis




38 men and 42 women with mean age of 26 (±5.3) 
years completed our protocol. No serious adverse 
events occurred. The baseline characteristics for all of 
the four symptoms had no clinically meaningful 
differences among the two groups. Table 1 shows 






(n=40) X2 P value
n % n %
1.56 .669
0 1 2.5 0 0
1 2 5 1 2.5
2 15 37.5 14 35
3 22 55 25 62.5
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baseline characteristics of the two groups for the 
rhinorrhea symptom.
Assessment of efficacy
Changes from baseline of individual symptomitems 
were shown in tables 2 through 5. Severity of all four 
studied symptoms was reduced by both Loratadine and 
Cetirizine, but as it is shown in these tables although 
Cetirizine had a little more better results, no 






(n=40) X2 P value
n % n %
2.77 0.428
None 10 25 5 12.5
1 Grade 12 30 13 32.5
2 Grade 10 25 15 37.5
3 Grade 8 20 7 17.5






(n=40) X2 P value
n % n %
0.672 0.822
None 12 30 12 30
1 Grade 9 22.5 8 20
2 Grade 11 27.5 12 30
3 Grade 8 20 8 20






(n=40) X2 P value
n % n %
0.۴٩٠ 0.٩٢١
None 8 20 7 17.5
1 Grade 6 15 6 15
2 Grade 22 55.5 21 52.5
3 Grade 4 10 6 15






(n=40) X2 P value
n % n %
0.٨١٣ 0.952
None 10 25 11 27.5
1 Grade 16 40 12 30
2 Grade 12 30 15 37.5
3 Grade 2 5 2 5
Eftekharian et al.                                                              Comparison of Loratadine and Cetirizine in Perennial Allergic Rhinitis
NBM                                                                           138                                   Novelty in Biomedicine 2015, 3, 135-9
statistically difference were seen between the two 
groups four all four symptoms. These two 
medications were most effective in reducing the 
sneezing (Table 4) and least effective on the nasal 
obstruction (Table 5).
Discussion
Skassa-Brocieket al.12 compared Loratadine, 
Mequitazine, and placebo in the symptomatic 
treatment of seasonal allergic rhinitis. Both 
Loratadine and Mequitazine induced a significant 
relief of nasal symptoms when these were compared 
to placebo.
In a multicentric randomized double-blind, placebo-
controlled survey on 611 patients by Noonans et al.14, 
Cetirizine HCl 10 mg taken once daily in the 
morning offers symptomatic relief that improves the 
health-related quality of life of adults suffering from 
SAR.
Chiang and his colleagues15 in a controlled trial of 
Cetirizine plus pseudoephedrine versus Loratadine 
plus pseudoephedrine for perennial allergic rhinitis 
showed that both combinations are efficacious for 
perennial allergic rhinitis and suggested that relief of 
sneezing and nasal congestion may be marginally 
better with the Cetirizine preparation.
In a study of 90 patients with allergic rhinitis by 
Nunes and Ladeira16, once-daily Cetirizine at 10mg 
or Loratadine at 10mg were both found to be 
significantly superior to placebo. In this study
Cetirizine was shown to be quantitatively superior to 
Loratadine, although the differences were not 
statistically significant.
In our study we have also found that although 
Cetirizine had little better results, no statistically 
difference could be seen between the two groups for 
reducing any of all four classic symptoms of allergic 
rhinitis. So we suggest that for choosing one of these 
drugs other factors should be considered. 
Greisner17 in a literature review found that Cetirizine 
had a shorter onset of action than Loratadine for all 
comparisons. In a parallel-group, double-blind study 
comparing the somnolence and motivation profiles of 
Loratadine and Cetirizine, Salmun et al.18
demonstrated that in patients aged 12 years or more, 
who had allergic rhinitis, Cetirizine use promoted 
somnolence and decreased motivation to perform 
activities during the workday compared with 
Loratadine.
As we have also already suggested Slater et al. 19after 
a valuable meta-analysis evaluating second-generation 
antihistamines, including Acrivastine, astemizole, 
Azelastine, Cetirizine, Ebastine, Fexofenadine, 
Ketotifen, Loratadine, Mizolastine and terfenadine
found that for allergic rhinitis, all agents are effective 
and the choice should be based on other factors. It 
must be also emphasized that the preference of the 
patient may be a very important factor in making a 
choice between these drugs.
Conclusion
Loratadine and Cetirizine both can reduce symptoms 
of the perennial allergic rhinitis but their difference is 
not statistically significant.
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